Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
Lavie, M.
Sarrazin, S.
Montserret, R.
Descamps, V.
Baumert, T. F.
Duverlie, G.
Seron, K.
Penin, F.
Dubuisson, J.
Journal of Virology, 2014
Muriel Lavie
Lavie Muriel
ORCID: 0000-0003-3308-811X
Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly.
10.1016/j.biochi.2017.06.009
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
10.1128/jvi.00048-17
Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.
10.1089/hum.2016.108
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
10.1128/jvi.01402-14
Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.
10.1016/j.virol.2013.09.019
Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
10.1007/s00262-012-1279-4
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.
10.1186/1471-2180-9-111
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.
10.1111/j.1462-5822.2007.01070.x
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system.
10.1002/hep.21406
Distribution and sequence analysis of a family of type ill-dependent effectors correlate with the phylogeny of Ralstonia solanacearum strains.
10.1094/mpmi.2004.17.8.931
PopP1, a new member of the YopJ/AvrRxv family of type III effector proteins, acts as a host-specificity factor and modulates aggressiveness of Ralstonia solanacearum.
10.1094/mpmi.2002.15.10.1058
Genome sequence of the plant pathogen Ralstonia solanacearum.
10.1038/415497a
Karin Seron
Seron Karin
ORCID: 0000-0002-9667-133X
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/jvi.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/jvi.01402-14
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity
10.2337/diabetes.55.02.06.db05-0971
Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women
10.1016/j.bbrc.2006.07.068
Genetic study of the CD36 gene In a French diabetic population
10.1016/s1262-3636(07)70143-x
GAD2 on chromosome 10p12 is a candidate gene for human obesity
10.1371/journal.pbio.0000068
Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii
10.1046/j.1432-1327.2000.01749.x
Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants
10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase
10.1016/s0166-0934(96)02166-0
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997)
10.1016/s0166-0934(96)02249-5
Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells
10.1006/viro.1996.0246
Gene expression from viral RNA genomes
10.1007/bf00039391
Vascular movement of plant viruses
10.1094/mpmi-9-0435
IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS
10.1016/s0923-2516(06)80049-x
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.
10.1016/j.antiviral.2016.07.011
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus
10.1101/325126
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource.
10.1016/j.jep.2020.112735
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.
10.1021/acsami.9b15032
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes".
10.1128/jvi.00309-18
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
A yeast t-SNARE involved in endocytosis.
10.1091/mbc.9.10.2873
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Jean Dubuisson
Dubuisson Jean
ORCID: 0000-0003-1626-7693
Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses
10.1016/j.jhep.2015.12.021
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
10.1371/journal.pone.0149064
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
10.1136/gutjnl-2015-311109
Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats
10.3390/v7122937
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
10.1039/c4nr03875d
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
HCV envelope glycoproteins in virion assembly and entry
10.2217/FVL.14.114
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
10.1128/JVI.00991-15
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice
10.1002/bab.1223
Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
10.1128/JVI.01745-13
HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin
10.3748/wjg.v20.i1.148
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Hepatitis C virus life cycle and lipid metabolism
10.3390/biology3040892
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/JVI.01402-14
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
10.3390/v6031149
Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation
10.1016/j.vaccine.2014.01.046
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Virology and cell biology of the hepatitis C virus life cycle - An update
10.1016/j.jhep.2014.06.031
Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization
10.1093/infdis/jit376
Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein
10.1128/JVI.02659-12
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics
10.1021/am403770q
Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies
10.2217/fvl.13.75
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Virus-neutralizing antibodies to hepatitis C virus
10.1111/jvh.12094
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
10.1136/gutjnl-2012-302048
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion
10.1074/jbc.M112.382341
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein
10.1099/vir.0.028092-0
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships
10.1099/vir.0.034314-0
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
HCV replication and assembly: a play in one act
10.2217/FVL.11.69
Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
10.1128/JVI.01332-10
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2
10.1128/JVI.02170-10
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
10.3390/v3101909
Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus
10.1128/JVI.01180-10
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/JVI.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/JVI.01190-09
Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets
10.3390/v2081782
NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus
10.1074/jbc.M110.122895
Recent Advances in Hepatitis C Virus Cell Entry
10.3390/v2030692
Role of lipid metabolism in hepatitis C virus assembly and entry
10.1042/BC20090125
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions
10.1128/JVI.01548-10
Enhanced anti-HCV activity of interferon alpha 17 subtype
10.1186/1743-422X-6-70
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
10.1111/j.1365-2893.2008.01058.x
N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins
10.1684/vir.2009.0270
Occludin, the final essential factor for HCV entry?
10.2217/FVL.09.13
Rapid synchronization of hepatitis C virus infection by magnetic adsorption
10.1016/j.jviromet.2008.11.015
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein
10.1128/JVI.02582-07
Hepatitis C virus entry into host cells
10.1007/s00018-007-7291-8
Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus
10.1086/589777
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent
10.1128/JVI.01443-07
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection
10.1128/JVI.01573-06
Hepatitis C virus proteins
10.3748/wjg.v13.i17.2406
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
10.1073/pnas.0705522104
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
10.1186/1742-4690-4-8
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors
10.1099/vir.0.82465-0
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes
10.1007/s00232-007-9003-6
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein
10.1128/JVI.00127-07
Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry
10.1128/JVI.02198-06
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles
10.1099/vir.0.81503-0
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans
10.1074/jbc.M602431200
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/JVI.00024-06
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI
10.1074/jbc.M602706200
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry
10.1099/vir.0.81932-0
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
10.1002/hep.21406
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/JVI.80.6.2832-2841.2006
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2
10.1128/JVI.79.21.13199-13208.2005
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets
10.1099/vir.0.81169-0
Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry
10.1128/JVI.79.24.15331-15341.2005
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/JVI.79.16.10826-10829.2005
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus
10.1002/hep.20542
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer
10.1099/vir.0.81140-0
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I
10.1074/jbc.M411600200
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/S0074-7696(05)45006-8
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins
10.1128/JVI.79.13.8400-8409.2005
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/JVI.78.6.2994-3002.2004
Functional hepatitis C virus envelope glycoproteins
10.1016/j.biolcel.2004.03.008
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions
10.1128/JVI.78.17.9224-9232.2004
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein
10.4049/jimmunol.173.1.446
Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication
10.1007/s00705-003-0291-6
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
Structural biology of hepatitis C virus
10.1002/hep.20032
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/JVI.78.22.12591-12602.2004
Another putative receptor for hepatitis C virus
10.1002/hep.510370327
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/JVI.77.19.10677-10683.2003
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
10.1074/jbc.M305289200
Characterization of the expression of the hepatitis C virus F protein
10.1099/vir.0.19065-0
Glycosylation of hepatitis C virus envelope proteins
10.1016/S0300-9084(03)00004-X
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
10.1084/jem.20021756
Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope
10.1128/JVI.77.2.813-820.2003
Topology of hepatitis C virus envelope glycoproteins
10.1002/rmv.391
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines
10.1128/JVI.76.3.1181-1193.2002
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Interaction of hepatitis C virus proteins with host cell membranes and lipids
10.1016/S0962-8924(02)02383-8
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines
10.1006/viro.2001.1212
Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment
10.1074/jbc.M111020200
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/JVI.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization
10.1053/jhep.2001.22175
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients
10.1128/JVI.75.17.8240-8250.2001
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/JVI.74.8.3623-3633.2000
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding
10.1099/0022-1317-81-12-2873
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
10.1128/JVI.74.2.702-709.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells
10.1046/j.1432-1327.2000.01111.x
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization
10.1074/jbc.M003003200
Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex
10.1099/0022-1317-80-4-887
Characterization of aggregates of hepatitis C virus glycoproteins
10.1099/0022-1317-80-12-3099
Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum
10.1023/A:1020228725997
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
10.1006/viro.1998.9202
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
Characterization of truncated forms of hepatitis C virus glycoproteins
10.1099/0022-1317-78-9-2299
SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H
10.1016/S0042-6822(95)80083-2
ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE
10.1006/viro.1993.1471
IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES
10.1007/BF01309747
EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(92)90010-B
IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-73-5-1293
MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV
10.1099/0022-1317-73-8-2031
MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4
10.1016/0378-1135(92)90037-T
PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT
10.1099/0022-1317-73-1-189
A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(91)90133-K
ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-3-715
BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS
10.1016/0378-1135(91)90132-Y
CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM
10.1099/0022-1317-72-5-1195
COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-5-1145
FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63
10.1136/vr.128.26.614
GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES
10.1007/BF01319227
TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS
10.1099/0022-1317-72-6-1429
Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis
10.1099/0022-1317-71-1-133
Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization
10.1099/0022-1317-71-3-647
EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE
10.1016/0378-1135(89)90022-9
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4
10.1016/0378-1135(89)90096-5
PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES
10.1099/0022-1317-70-7-1743
BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS
10.1016/0378-1135(88)90015-6
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly
10.1128/JVI.00048-17
Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination
10.1111/pbi.12743
Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly
10.1016/j.biochi.2017.06.009
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics
10.1016/j.jviromet.2017.04.009
Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes
10.1128/JVI.00478-17
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
10.1111/jvh.12767
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
10.1016/j.virol.2017.10.019
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein
10.1053/j.gastro.2017.09.020
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
10.1007/s40271-017-0232-1
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
10.1371/journal.pone.0145105
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
10.1111/jvh.12433
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain
10.1128/JVI.00939-18
HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region
10.1099/jgv.0.001074
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
10.3389/fimmu.2018.00910
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication
10.1101/469361
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/JVI.02009-18
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir
10.1016/j.antiviral.2019.05.002
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E
10.1051/medsci/2018299
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
10.1371/journal.pone.0198226
Function of the HCV E1 envelope glycoprotein in viral entry and assembly
10.2217/fvl-2018-0180
Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV
10.1007/978-1-4939-8976-8_2
Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit
10.1016/j.jcv.2019.104206
A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice
10.1186/s12879-019-4571-5
Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver
10.3390/cells8101296
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
10.1021/acsami.9b15032
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.ra119.008964
Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection
10.1111/tra.12680
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
10.1101/2020.04.22.056754
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Les coronavirus, ennemis incertains
10.1051/medsci/2020113
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
10.1016/j.jep.2020.112735
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
10.3390/microorganisms9020339
Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds
10.3390/pathogens10070861
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
